Sources of New Product Innovation Big Pharma

Mike Wokasch had the following post in his Pharma Reform blog on a topic that has been discussed here often, namely the need to adopt new R&D models in Big Pharma.  Mike gives 5 concrete suggestions for how the relationship between big pharma and biotech needs to change to become more productive in the coming years.  These include changes in managing the science and in managing the business relationship -- and the expectations associated with both.

Posted by Bruce Lehr May 17th 2010.

Comments

[Bruce Lehr]

Here's another example of a new research center that Bayer is putting together in San Francisco teaming with academic insitutions and new biotechs.
http://www.pharmanews.eu/bayer/525-bayer-schering-pharma-enhances-us-research-strategy-with-new-innovation-center

[Bruce Lehr]

The pharma executives in this poll from the Pharmatimes seem pretty pessimistic about their chances of internal innovation. Let's hope they embrace some of the more creative models emerging.
http://www.pharmatimes.com/WorldNews/article.aspx?id=17877&src=EWorldNews

[Bruce Lehr]

Speak of the devil. Here is a new deal that Pfizer just announced today in a collaboration with Wash U that will pay the university $22.5 M over 5 years to assist with application identification for existing compounds in Pfizer portolio.
http://www.rttnews.com/ArticleView.aspx?Id=1307608